AnaptysBio, Inc. (ANAB) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares are up ~18% over 21 days and ~13% above the 21‑day SMA after a large one‑day jump, with clear near‑term catalysts: a Q2 2026 spin‑off of First Tracks Biotherapeutics, active Phase 1b enrollment, and ongoing Delaware Chancery litigation milestones. Event‑driven traders can target additional upside on spin‑off and legal/process news, with elevated pullback risk from high leverage and rich valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Profit volatility • Strong liquidity • Excessive leverage ANAB exhibits extreme intra-year profitability volatility with strong liquidity but heavy reinvestment and very high leverage amid an expensive equity valuation.
Price Behavior
Key Price Behavior Insights: • Higher highs/lows • Spike then pullback • Support cluster Support Level: $49.70–$50.30 Resistance Level: $60.55 ANAB is in a clear short-term uptrend over the last month, rallying ~15% from ~$47.90 to $55.41 with higher highs/lows but showing elevated volatility after a sharp spike to $60.55 and pullback to $55.41.
Sentiment & News
Key News Insights: • Planned spin‑off • ANB033 progress • Royalty upside AnaptysBio plans a Q2 2026 spin‑off into First Tracks, reported $311M year‑end cash, beat Q4 EPS, advanced ANB033 trials and signaled sizable royalty upside from GSK's Jemperli.
AI Summary
ANAB has shifted from a binary clinical punt to a hybrid royalty-driven cash generator with retained pipeline optionality—treat it as a quasi-royalty/royalty-arbitrage investment where upside depends on sustained Jemperli sales and a clean legal/spin-off execution, and downside is concentrated in royalty shortfalls, adverse litigation, or failed spin execution.
Description
AnaptysBio is a clinical-stage biotechnology company developing therapeutic antibody candidates for inflammatory and immuno-oncology indications. Its pipeline includes programs directed at interleukin-36 receptor, modulators of PD-1 signaling, and BTLA, with assets progressing through preclinical and clinical milestones. The company maintains collaborations and licensing arrangements with major industry and research partners, and is headquartered in San Diego, California; it was incorporated in 2005.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 5 | Mar 12 | ANAB | AnaptysBio, Inc. | Shares are up ~18% over 21 days and ~13% above the 21‑day SMA after a large one‑day jump, with clear near‑term catalysts: a Q2 2026 spin‑off of First Tracks Biotherapeutics, active Phase 1b enrollment, and ongoing Delaware Chancery litigation milestones. Event‑driven traders can target additional upside on spin‑off and legal/process news, with elevated pullback risk from high leverage and rich valuation. | Closed | +11.4% |